Integrated waveguides and deterministically positioned nitrogen vacancy centers in diamond created by femtosecond laser writing

Diamond's nitrogen vacancy (NV) center is an optically active defect with long spin coherence times, showing great potential for both efficient nanoscale magnetometry and quantum information processing schemes. Recently, both the formation of buried 3D optical waveguides and high quality single NVs in diamond were demonstrated using the versatile femtosecond laser-writing technique. However, until now, combining these technologies has been an outstanding challenge. In this work, we fabricate laser written photonic waveguides in quantum grade diamond which are aligned to within micron resolution to single laser-written NVs, enabling an integrated platform providing deterministically positioned waveguide-coupled NVs. This fabrication technology opens the way towards on-chip optical routing of single photons between NVs and optically integrated spin-based sensing

Rare Earth-Activated Silica-Based Nanocomposites

Two different kinds of rare earth-activated glass-based nanocomposite photonic materials, which allow to tailor the spectroscopic properties of rare-earth ions: (i) Er3+-activated SiO2-HfO2 waveguide glass ceramic, and (ii) core-shell-like structures of Er3+-activated silica spheres obtained by a seed growth method, are presented

Comparison of energy transfer between Terbium and Ytterbium ions in glass and glass ceramic: Application in photovoltaic

The structural and optical properties of thin layers based on 70%SiO 2 –30%HfO 2 doped with different concentra- tion of rare earth ions (terbium and ytterbium) have been studied with a view to integrating them in a photovoltaic cell as a spectral conversion layer in order to improve its efficiency, by using down-conversion process. These thin films were synthesized by using sol gel technique and deposited on the pure silica substrate by dip-coating method. The DC layer can be placed on the front side of a solar cell and can enhance the current by converting ultraviolet (UV) photons into a large number of visible photons. In present study two series of samples are compared, the first series corresponds to samples treated at 900 °C (glass- S) while the second series concerns samples treated at 1000 °C (glass-ceramic- SC). These series are based on 70SiO 2 –30HfO 2 activated by different molar concentrations of rare earths [Tb + Yb]/[Si + Hf] = 7%, 9%, 12%, 15%, 17%, 19% and 21%. Photoluminescence results of reference samples (without Yb 3 + ) showed an emission from 5 D 4 to 7 F J ( J = 3, 4, 5, 6) level characteristic transitions of Tb 3 + , with a maximum peak in the green centered at 543.5 nm cor- responding to the 5 D 4 →7 F 5 transition. For the co-doped samples a clear NIR PL emission around 980 nm was detected, due to the 2 F 5/2 →2 F 7/2 transition of Yb 3 + ions. From luminescence decay curves of Tb 3 + maximum emission peak ( 7 F 5 →5 D 4 transition at 543.5 nm) we have identified the energy transfer efficiency. The quantum efficiency increases by increasing the total [Tb + Yb] concentration. The most significant yield was achieved with [Tb + Yb] = 19%, the maximum quantum transfer efficiency obtained was 190% for glass-ceramic samples and 161% for glassy one

Silver doping of silica-hafnia waveguides containing Tb3+/Yb3+ rare earths for downconversion in PV solar cells

The aim of this paper is to study the possibility to obtain an efficient downconverting waveguide which combines the quantum cutting properties of Tb3+/Yb3+ codoped materials with the optical sensitizing effects provided by silver doping. The preparation of 70SiO(2)-30HfO(2) glass and glass-ceramic waveguides by sol-gel route, followed by Ag doping by immersion in molten salt bath is reported. The films were subsequently annealed in air to induce the migration and/or aggregation of the metal ions. Results of compositional and optical characterization are given, providing evidence for the successful introduction of Ag in the films, while the photoluminescence emission is strongly dependent on the annealing conditions. These films could find potential applications as downshifting layers to increase the efficiency of PV solar cells. (C) 2016 Elsevier B.V. All rights reserved

Sol–gel-derived photonic structures handling erbium ions luminescence

The sol–gel technique is a very flexible, relatively simple, and low-cost method to fabricate many different innovative photonic structures characterized by specific functionalities. During synthesis, starting from the molecular level, compounds or composites with well controlled composition can be obtained as thin films, powders or monoliths. These materials can be used to prepare such structures as waveguides, photonic crystals, coatings, and bulk glasses including spheres, rings and other geometries exploited in optical resonators fabrication. This article presents some results obtained by the authors in the field of the sol–gel-derived photonic structures. To emphasise the scientific and technological interest in this kind of systems and the versatility of the sol–gel route, the glass-based nano and micrometer scale range systems are discussed. Particularly, the following systems are described: silica–hafnia glass and glass–ceramic planar waveguides, nanosized tetraphosphates, and silica colloidal crystals. The attention is focused on the spectroscopic properties of Er3+-activated materials that due to the light emission can be used in the integrated optics area covering application in sensing, biomedical diagnostic, energy conversion, telecommunication, lighting, and photon management

Protocole de fabrication par voie colloïdalede cristaux photoniques 3D

session 7 " Cristaux photoniques "National audienceNous présentons ici les détails d'un processus sol-gel utilisé pour synthétiser des sphères de silice, en portant une attention particulière aux conditions expérimentales permettant de contrôler leur taille. Nous avons élaboré un protocole dans le but d'obtenir des microsphères avec une faible dispersion, et démontré que de larges domaines cristallins ordonnés d'opale synthétique montrant une " stop band " peuvent être produits en quelques jours par déposition verticale et sédimentation assistée par évaporation. La microscopie électronique à balayage a été employée pour caractériser les échantillons. Des mesures de réflexion et transmission ont été effectuées pour mettre en évidence la haute qualité des opales réalisées

Fabrication and characterization of Er+3 doped SiO2/SnO2 glass-ceramic thin films for planar waveguide applications

Glass-ceramics are a kind of two-phase materials constituted by nanocrystals embedded in a glass matrix and the respective volume fractions of crystalline and amorphous phase determine the properties of the glass-ceramics. Among these properties transparency is crucial in particular when confined structures, such as, dielectric optical waveguides, are considered. Moreover, the segregation of dopant rare-earth ions, like erbium, in low phonon energy crystalline medium makes these structures more promising in the development of waveguide amplifiers. Here we are proposing a new class of low phonon energy tin oxide semiconductor medium doped silicate based planar waveguides. Er3+ doped (100-x) SiO2- xSnO2 (x= 10, 20, 25 and 30mol%), glass-ceramic planar waveguide thin films were fabricated by a simple sol-gel processing and dip coating technique. XRD and HRTEM studies indicates the glass-ceramic phase of the film and the dispersion of ~4nm diameter of tin oxide nanocrystals in the amorphous phase of silica. The spectroscopic assessment indicates the distribution of the dopant erbium ions in the crystalline medium of tin oxide. The observed low losses, 0.5±0.2 dB/cm, at 1.54 ?m communication wavelength makes them a quite promising material for the development of high gain integrated optical amplifiers

Exploratory data on the clinical efficacy of monoclonal antibodies against SARS-CoV-2 Omicron variant of concern

Background: Recent in-vitro data have shown that the activity of monoclonal antibodies (mAbs) targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) varies according to the variant of concern (VOC). No studies have compared the clinical efficacy of different mAbs against Omicron VOC. Methods: The MANTICO trial is a non-inferiority randomised controlled trial comparing the clinical efficacy of early treatments with bamlanivimab/etesevimab, casirivimab/imdevimab, and sotrovimab in outpatients aged 50 or older with mild-to-moderate SARS-CoV-2 infection. As the patient enrolment was interrupted for possible futility after the onset of the Omicron wave, the analysis was performed according to the SARS-CoV-2 VOC. The primary outcome was coronavirus disease 2019 (COVID-19) progression (hospitalisation, need of supplemental oxygen therapy, or death through day 14). Secondary outcomes included the time to symptom resolution, assessed using the product-limit method. Kaplan-Meier estimator and Cox proportional hazard model were used to assess the association with predictors. Log rank test was used to compare survival functions. Results: Overall, 319 patients were included. Among 141 patients infected with Delta, no COVID-19 progression was recorded, and the time to symptom resolution did not differ significantly between treatment groups (Log-rank Chi-square 0.22, p 0.90). Among 170 patients infected with Omicron (80.6% BA.1 and 19.4% BA.1.1), two COVID-19 progressions were recorded, both in the bamlanivimab/etesevimab group, and the median time to symptom resolution was 5 days shorter in the sotrovimab group compared with the bamlanivimab/etesevimab and casirivimab/imdevimab groups (HR 0.53 and HR 0.45, 95% CI 0.36-0.77 and 95% CI 0.30-0.67, p<0.01). Conclusions: Our data suggest that, among adult outpatients with mild-to-moderate SARS-CoV-2 infection due to Omicron BA.1 and BA.1.1, early treatment with sotrovimab reduces the time to recovery compared with casirivimab/imdevimab and bamlanivimab/etesevimab. In the same population, early treatment with casirivimab/imdevimab may maintain a role in preventing COVID-19 progression. The generalisability of trial results is substantially limited by the early discontinuation of the trial and firm conclusions cannot be drawn. Funding: This trial was funded by the Italian Medicines Agency (Agenzia Italiana del Farmaco, AIFA). The VOC identification was funded by the ORCHESTRA (Connecting European Cohorts to Increase Common and Effective Response to SARS-CoV-2 Pandemic) project, which has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement number 101016167. Clinical trial number: NCT05205759